Biocon Pharma Inc. Initiates Class II Recall for Atorvastatin Calcium Due to Dissolution Failure
Biocon Pharma Inc. has initiated a Class II recall for Atorvastatin Calcium Tablets USP 40 mg across the U.S. due to failed dissolution specifications. This impacts 2184 bottles (1000-count) from lot AVC24035, manufactured by Recipharm Pharmaservices PVT, Ltd in India. Procurement teams must secure alternative sources, while regulatory affairs must ensure robust CAPA to maintain market access.
FDA Class II Recall: Biocon Pharma's Atorvastatin Calcium Fails Dissolution Specifications
The U.S. Food and Drug Administration (FDA) has announced a Class II recall, identified as D-0306-2025, initiated by Biocon Pharma Inc., headquartered in Iselin, NJ, for specific lots of Atorvastatin Calcium Tablets USP 40 mg. This critical event, initiated on March 17, 2025, and classified by the FDA on March 28, 2025, directly impacts the availability and therapeutic reliability of a widely prescribed statin in the U.S. market. The core issue identified is a failure to meet dissolution specifications, with tested results falling below the established limits. For procurement directors, this means immediate action is required to identify and quarantine affected stock. The compromised dissolution profile directly impacts the drug's bioavailability, potentially leading to sub-therapeutic effects for patients relying on Atorvastatin Calcium for hyperlipidemia management. The affected product, identified by NDC 70377-079-13, is distributed in 1000-count bottles, with lot number AVC24035 and an expiration date of March 31, 2026. A total of 2184 bottles are subject to this recall, distributed nationwide across the U.S. This incident underscores the necessity for rigorous quality assurance throughout the pharmaceutical supply chain, particularly for high-volume generic medications.
Manufacturing Origin and Supply Chain Vulnerabilities for Atorvastatin Calcium
The recalled Atorvastatin Calcium Tablets USP 40 mg, marketed by Biocon Pharma Inc. from its Iselin, NJ base, were manufactured by Recipharm Pharmaservices PVT, Ltd, located in Bengaluru, India. This highlights a common structure in the global pharmaceutical industry where marketing authorization holders rely on contract manufacturing organizations (CMOs) in diverse geographies. For supply chain VPs, this structure introduces inherent complexities, as the quality oversight extends beyond the primary recalling entity to its manufacturing partners. The incident necessitates a thorough review of quality agreements and audit processes for all third-party manufacturers, especially those located internationally, to ensure compliance with FDA Good Manufacturing Practices (GMP). The physical distance and differing regulatory environments can complicate immediate remediation efforts and root cause analysis. The nationwide distribution pattern in the U.S. for this recalled product means that the impact of the dissolution failure is geographically widespread, affecting numerous healthcare systems and retail pharmacies. Business development executives should note that such recalls can lead to shifts in market share as customers seek more stable and compliant sources.
Commercial Impact and Strategic Procurement for Atorvastatin Supply
Atorvastatin Calcium remains a cornerstone therapy for dyslipidemia, with substantial market demand. The recall of 2184 bottles, each containing 1000 tablets of the 40 mg strength, from lot AVC24035, represents a tangible reduction in available supply for a critical generic medication. While the overall market for Atorvastatin is robust with multiple suppliers, any disruption from a significant player like Biocon Pharma Inc. creates immediate challenges for inventory management and patient access. Procurement directors must prioritize rapid assessment of their current stock, identifying and segregating the affected NDC 70377-079-13 product to prevent its distribution. This event underscores the financial implications of quality failures, including costs associated with recall logistics, potential product replacement, and damage to supplier reputation. For business development executives, this situation presents both risks and opportunities. While Biocon Pharma Inc. navigates the recall, competitors with robust Atorvastatin Calcium supply chains may see increased demand. Procurement teams should not only seek immediate alternative sources but also engage in long-term strategic planning, including qualifying new suppliers and diversifying geographic sourcing.
Regulatory Compliance and Future Outlook for Biocon Pharma's US Market Access
The "Ongoing" status of recall D-0306-2025 indicates that Biocon Pharma Inc. is actively engaged in the recall process, working with the FDA to manage the affected product. However, the underlying issue of failed dissolution specifications for Atorvastatin Calcium necessitates a comprehensive investigation and robust corrective and preventive actions (CAPA) by both Biocon Pharma Inc. and its manufacturer, Recipharm Pharmaservices PVT, Ltd. Regulatory affairs heads must ensure that the root cause analysis extends beyond the immediate batch to encompass the entire manufacturing process, analytical methods, and quality management systems for ANDA216436. The FDA will expect a detailed response outlining how similar failures will be prevented in the future, impacting all relevant product lines from the Bengaluru, India facility. The consequences of inadequate remediation can be severe, potentially leading to further recalls, increased inspection frequency, or even an Import Alert for products manufactured at the Recipharm facility in India, which would effectively block their entry into the U.S. market. For Biocon Pharma Inc., this could jeopardize its market standing for Atorvastatin Calcium and potentially other products.